Fig. 6
A Percent inhibition of HIV1VB28 and HIV1UG070 of free TNF, AuNPs, and AuNP-TNF in TZM-bl cell line with different concentrations, B Inhibitory concentrations (IC50) of infected PBMCs treated with compounds against HIV-1 strains were used in this study, C Therapeutic index (TI) of free TNF, AuNPs, and AuNP-TNF in TZM-bl cell line & PBMCs associated with both HIV-1 strains, D HIV-1 p24 Gag antigen level (pg/mL) in 1, 3, and 5 days post-infection in MΦ exposed to the compounds. (***denotes p ≤ 0.0001, the significant difference is in comparison with the drug control, TNF)